Laddar...

The Recent Medicinal Chemistry Development of Jak2 Tyrosine Kinase Small Molecule Inhibitors

Since the discovery of the Jak2-V617F mutation as the causative agent in a large number of myeloproliferative neoplasms (MPNs), there has been a drive to develop Jak2 specific inhibitors that can be used in therapy for MPN patients and other Jak2-related pathologies. Over the past few years, a numbe...

Full beskrivning

Sparad:
Bibliografiska uppgifter
Huvudupphovsmän: Baskin, Rebekah, Majumder, Anurima, Sayeski, Peter P.
Materialtyp: Artigo
Språk:Inglês
Publicerad: 2010
Ämnen:
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC3636533/
https://ncbi.nlm.nih.gov/pubmed/21062251
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!